The novel phospho‐non‐steroidal anti‐inflammatory drugs, OXT‐328, MDC‐22 and MDC‐917, inhibit adjuvant‐induced arthritis in rats
Authors:
Open Access
- 22 December 2010
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 162 (7) , 1521-1533
Abstract
BACKGROUND AND PURPOSEThe use of non‐steroidal anti‐inflammatory drugs (NSAIDs) in the treatment of rheumatoid arthritis (RA) is limited by their toxicity. We evaluated the anti‐inflammatory efficacy and safety of three novel modified NSAIDs, phospho‐aspirin, phospho‐ibuprofen and phospho‐sulindac.EXPERIMENTAL APPROACHWe determined the anti‐inflammatory effects and gastrointestinal safety of the phospho‐NSAIDs in the rat adjuvant arthritis model and studied their mechanism of action in cultured cells, Cytokines were measured withelisaand activation of nuclear factor‐κB (NF‐κB) by immunohistochemistry.KEY RESULTSAll three phospho‐NSAIDs showed less gastrointestinal toxicity than their parent compounds and demonstrated strong anti‐inflammatory effects, essentially reversing joint inflammation and oedema. They have a broad but not uniform effect on the expression of relevant cytokines, in general decreasing IL‐6 and IL‐1β and increasing IL‐10 levels in rat plasma and cultured cells. Phospho‐sulindac and phospho‐ibuprofen but not phospho‐aspirin suppressed PGE2productionin vitro, whereas phospho‐aspirin (in contrast to aspirin) showed the same effectin vivo. In joint tissues, phospho‐aspirin inhibited NF‐κB activation, and suppressed inflammation and bone resorption. Phospho‐aspirin also inhibited Jurkat T cell proliferation. In general, phospho‐aspirin had greater efficacy but different effects upon inflammatory mediators compared with aspirin. The chemical modification of the parent NSAIDs seems crucial for their safety and efficacy.CONCLUSIONS AND IMPLICATIONSPhospho‐aspirin, phospho‐ibuprofen and phospho‐sulindac were safer than their parent NSAIDs, were highly effective in rat adjuvant arthritis and inhibited many key mediators in the pathophysiology of RA. These novel compounds are promising candidate drugs for the treatment of RA and merit further evaluation.Keywords
This publication has 37 references indexed in Scilit:
- Phospho-Sulindac (OXT-328), a Novel Sulindac Derivative, Is Safe and Effective in Colon Cancer Prevention in MiceGastroenterology, 2010
- Functions of nuclear factor κB in boneAnnals of the New York Academy of Sciences, 2010
- Cytokines and Cytokine Profiles in Human Autoimmune Diseases and Animal Models of AutoimmunityMediators of Inflammation, 2009
- NF- B as a Critical Link Between Inflammation and CancerCold Spring Harbor Perspectives in Biology, 2009
- A Novel Sulindac Derivative That Does Not Inhibit Cyclooxygenases but Potently Inhibits Colon Tumor Cell Growth and Induces Apoptosis with Antitumor ActivityCancer Prevention Research, 2009
- Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effectCarcinogenesis, 2009
- The Thioredoxin System Mediates Redox-Induced Cell Death in Human Colon Cancer Cells: Implications for the Mechanism of Action of Anticancer AgentsCancer Research, 2008
- The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritisArthritis Research & Therapy, 2008
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Animal Models of Arthritis: Relevance to Human DiseaseToxicologic Pathology, 1999